ATR and cancer: p53 plays a key role in G1 checkpoint control and TP53 mutations (present in almost 100% of HGSOC [5]) could render cancers more sensitive to ATR inhibition than p53-proficient cells, however the data has been inconsistent [15,16,17,18].